FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

| l | OMB APPROVAL | | | | | | | | | |
|---|-------------------------|-----------|--|--|--|--|--|--|--|--|
| | OMB Number: | 3235-0287 | | | | | | | | |
| l | Estimated average burde | en | | | | | | | | |
| l | hours per response: | 0.5 | | | | | | | | |

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| ı | GREG J | <u>A</u> | AVADEL PHARMACEUTICALS PLC [AVDL] | | | | | | | | eck all appli Direct | cable) or (give title | 10% Owner ve title Other (specify below) | | vner | | | | | |
|--|--|------------|-------------------------------------|------------------------------|-------|--|---|--|---|---------------|-------------------------|-----------------------------|---|---|------------------------------------|--|---|--|--|--|
| (Last) (First) (Middle) C/O AVADEL PHARMACEUTICALS PLC BLOCK 10-1 BLANCHARDSTOWN CORPORATE PARK | | | | | | | 3. Date of Earliest Transaction (Month/Day/Year) 12/12/2017 | | | | | | | | See Remarks | | | | | |
| (Street) DUBLIN L2 15 | | | | | 4. | 4. If Amendment, Date of Original Filed (Month/Day/Year) | | | | | | | | Individual or Joint/Group Filing (Check Applicable ne) X Form filed by One Reporting Person Form filed by More than One Reporting Person | | | | | | |
| (City) (State) (Zip) | | | | | | | | | | | | | | | | | | | | |
| | | Та | ble I - Nor | n-Deri | vativ | /e S | ecurities | Ac | quired, | Dis | posed o | f, or Be | neficial | ly Owned | l | | | | | |
| 1. Title of Security (Instr. 3) 2. Transa Date (Month/D | | | | | | Execution Date, | | | 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) of Disposed Of (D) (Instr. 3, 4) 5) | | | | Benefic | es ally Following | Form (D) o | : Direct r Indirect str. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | | | |
| | | | | | | | | | Code | v | Amount | ount (A) or Pr | | Transac | Transaction(s) (Instr. 3 and 4) | | | | | |
| ADSs ⁽¹⁾ 12/12/ | | | | | | | /2017 | | A | | 22,50 | 22,500 A | | 33, | 33,100 ⁽²⁾ | | D | | | |
| | | | Table II - | | | | curities <i>i</i> Is, warra | | | | | | | Owned | | | | | | |
| 1. Title of Derivative Security (Instr. 3) | ative Conversion Date Execution Date, rity or Exercise (Month/Day/Year) if any | | ate, | 4. Transa Code (8) | | | | 6. Date Exercis Expiration Date (Month/Day/Yea | | of Securities | | ties ng e Security | 8. Price of Derivative Security (Instr. 5) | | ve es ally ng d | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | Beneficial Ownership t (Instr. 4) | | | |
| | | | | | Code | v | (A) | (D) | Date Exercisal | | Expiration Date | Title | Amount or Number of Shares | oer (1 | | | | | | |
| Stock Option (right to buy) | \$10.4 | | | | | | | | (3) | | 12/14/2026 | ADSs ⁽¹⁾ | 150,000 | | 150,0 | 000 | D | | | |
| Stock Option (right to buy) | \$8.95 | 12/12/2017 | | | A | | 100,000 | | (4) | | 12/12/2027 | ADSs ⁽¹⁾ | 100,000 | \$8.95 | 100,0 | 000 | D | | | |

Explanation of Responses:

- 1. The issuer's "ADSs" are American Depositary Shares, with each ADS representing one ordinary share, nominal value \$0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts.
- 2. Represents 22,500 restricted shares granted under the issuer's Omnibus Incentive Compensation Plan on 12/12/2017, under which 15,000 ADSs will vest and be issued on the second anniversary of the grant date and the remaining 7,500 ADSs will vest and be issued on the third anniversary of the grant date (with vesting of these restricted shares subject to the reporting person remaining in continuous service until the applicable anniversary of the date of grant).
- 3. Options become exercisable as to 37,500 ADSs on each of the first four anniversaries after the 12/14/2016 grant date.
- 4. Options become exercisable as to 25,000 ADSs on each of the first four anniversaries after the 12/12/2017 grant date.

Remarks:

Executive VP, Chief Commercial Officer

/s/ Phillandas T. Thompson as attorney in fact for Greg J. 12/14/2017 **Divis**

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.